Kerem Can Alp
Product Manager, Commercial
Expertise:
Kerem has over a decade of experience in the pharmaceutical industry, having worked in various capacities within European and US-based organizations. Throughout his career, he has held key roles in business development and strategy, focusing on Pharma, CDMO, and CSO companies.
Currently, Kerem works as a member of the Commercial Strategy team within EVERSANA, where he is responsible for EVERSANA COMPLETE Commercialization® and Integrated commercial assessments and projects in both the United States and Europe.
Kerem has an M.A. in Political Economy from the University of Chicago where he was a Fulbright Scholar.
Articles by Kerem Can Alp
Unlocking Your Full North American Potential: Coordinating Launches in The U.S. and Canada
Discover the groundbreaking strategy that could redefine pharmaceutical launches and propel your product’s success across North America. In the realm of pharmaceutical launches, a paradigm shift is underway, challenging the conventional sequential approach and calling for a bolder strategy that reaps unparalleled benefits. “Unlocking Your Full North American Potential: Coordinating Launches in The U.S. and Canada” presents a revolutionary perspective on launch synchronization, dispelling myths and highlighting the untapped potential of a united North American launch. Authored by industry thought leaders Deborah Brown, Ryan H. Brown, Kerem Can Alp, Adam Hardy, and Charles Pirraglia, this paper unveils the transformative potential of parallel launches in the U.S. and Canada. Departing from […]
Successfully Navigating Self-Commercialisation in Europe
Introduction As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,, Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of its complexity, can be intimidating and may deter some companies from launching themselves. Companies may prefer to out-license or sign agreements with distributors, which are the more traditional routes to market. However, these agreements result in less control for the manufacturer regarding all aspects of the launch strategy and decreased long-term company awareness and revenue […]
Successful Launches in Europe: Complex, but Not Complicated?
Europe represents a major pharmaceutical market – it accounts for 22% of the global market, second only to the U.S. in terms of market size and has a large population of over 500 million. Understandably, pharmaceutical and biotechnology companies looking to maximise their revenue consider Europe to be a key focus[1]. Indeed, looking at first-time drug launches by biotech companies, between 2010 and 2020, two-thirds of U.S. launches were followed by launches in other countries[2]. Our paper, “Successful Launches in Europe: Complex but Not Complicated,” discusses the challenges and opportunities associated with launching a pharmaceutical product in Europe. This paper emphasizes the need for pharmaceutical companies to adopt a comprehensive […]